<tbody id="ff6si"><div id="ff6si"></div></tbody>
  • <track id="ff6si"></track>

    1. <option id="ff6si"></option>

    2. <option id="ff6si"></option>
      1. <track id="ff6si"></track>

          Fresenius Group Overview

          Fresenius Kabi

          Industrial production of infusion solutions at Fresenius Kabi's plant in Friedberg.

          Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients.

          Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection and processing of blood and cell components.

          With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

          Fresenius Kabi employs over 38,000 people worldwide. In 2018 the company reported sales of more than €6.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA health care group.

           

           

          Key figures (IFRS)
          € in millions

          2018

          2017

          Change

          Sales

          6,544

          6,358

          + 3 %

          EBIT

          1,139

          1,177

          - 3 %

          Net income

          742

          702

          + 6 %

          Operating cash flow

          1,040

          1,010

          + 3 %

          Capital expenditure/acquisitions

          615

          585

          + 5 %

          R & D expenses 534

          427

          + 25 %

          Employees (December 31)

          37,843

          36,380

          + 4 %

          • Some figures adjusted for special items
          • Net income = Net income attributable to shareholders of Fresenius Kabi
          青草青青